Abbott Laboratories $ABT Position Raised by Absher Wealth Management LLC

Key Points

• Absher Wealth Management raised its stake in Abbott by 24.7% in Q4 to 197,281 shares (about $24.7M), and institutional investors now own roughly 75.18% of the company’s stock.
• Abbott beat Q1 estimates with EPS of $1.15 (vs. $1.14) and revenue of $11.16B (+7.8% YoY), issued FY2026 guidance of $5.38–$5.58 EPS and Q2 guidance of $1.25–$1.31, and declared a $0.63 quarterly dividend (2.7% yield).
• Several analysts have trimmed price targets recently (Bank of America, Mizuho, UBS, Evercore, etc.), leaving an average target of $119.43 and a consensus rating of Moderate Buy, indicating mixed-to-cautious sentiment that could cap near‑term upside.

Absher Wealth Management LLC raised its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 197,281 shares of the healthcare product maker's stock after purchasing an additional 39,135 shares during the quarter. Abbott Laboratories comprises 2.9% of Absher Wealth Management LLC's portfolio, making the stock its 22nd largest holding. Absher Wealth Management LLC's holdings in Abbott Laboratories were worth $24,717,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gemmer Asset Management LLC boosted its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker's stock valued at $368,000 after purchasing an additional 78 shares in the last quarter. Global Financial Private Client LLC raised its holdings in shares of Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker's stock worth $331,000 after purchasing an additional 79 shares in the last quarter. Citizens & Northern Corp lifted its stake in Abbott Laboratories by 0.4% during the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker's stock valued at $2,930,000 after purchasing an additional 79 shares during the last quarter. American National Bank of Texas boosted its holdings in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker's stock worth $427,000 after buying an additional 79 shares in the last quarter. Finally, Nia Impact Advisors LLC grew its position in Abbott Laboratories by 2.2% in the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock worth $504,000 after buying an additional 79 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares of the company's stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large-market tailwind: a new IoT medical‑devices market report forecasts strong secular growth for connected and remote-monitoring devices through 2036, supporting Abbott’s device franchises (long-term demand upside). IoT Medical Devices Market Research and Global Forecast Report 2026-2036
• Positive Sentiment: “Most oversold” commentary: coverage noting Abbott as one of the most oversold healthcare names may prompt value-oriented buying and short-covering, supporting near-term rebounds. Abbott is the most oversold healthcare stock as Q1 earnings roll on
• Neutral Sentiment: Elevated investor attention: Zacks and Yahoo note heavy search/interest in ABT, which can increase volatility and trading volume but doesn’t directly change fundamentals. Investors Heavily Search Abbott Laboratories (ABT)
• Neutral Sentiment: Competitive/industry note: unrelated coverage of Intuitive Surgical’s platform refresh highlights competitive dynamics in surgical robotics/devices — worth watching for competitive impact but not an immediate Abbott-specific catalyst. How ISRG Just Secured The U.S. Market
• Negative Sentiment: UBS trims price target to $135 — a reduction in analyst optimism that can cap upside and weigh on investor sentiment despite the company’s solid Q1. UBS Group Cuts Abbott Laboratories NYSE: ABT Price Target to $135.00
• Negative Sentiment: Argus issues a pessimistic forecast for ABT — adds to negative analyst noise and could pressure the stock if other firms follow suit. Argus Issues Pessimistic Forecast for Abbott Laboratories NYSE: ABT Stock Price
• Negative Sentiment: Daiwa downgrades ABT to neutral and sets a $92 target — implies limited near-term upside and may influence short‑term seller behavior. Finviz (Daiwa downgrade note)
• Negative Sentiment: Barclays lowers expectations for ABT — another bearish signal from the sell side that contributes to downward pressure on sentiment and potential re-rating risk. Barclays Has Lowered Expectations for Abbott Laboratories NYSE: ABT Stock Price

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ABT shares. Bank of America cut their price objective on Abbott Laboratories from $150.00 to $120.00 and set a "buy" rating for the company in a research report on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, January 26th. Mizuho reduced their target price on Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a report on Friday, April 17th. Argus decreased their price target on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Evercore cut their price objective on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $119.43.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $92.45 on Friday. The firm has a market cap of $161.02 billion, a price-to-earnings ratio of 25.90, a P/E/G ratio of 1.53 and a beta of 0.79. Abbott Laboratories has a 1 year low of $90.72 and a 1 year high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The business has a fifty day simple moving average of $106.39 and a 200 day simple moving average of $117.64.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the prior year, the firm posted $1.09 EPS. The business's revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.49 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories's dividend payout ratio is currently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.